News

This week, Nature Medicine published results from an innovative trial in anhedonia. Anhedonia, or lack of pleasure, is a key symptom in a number of mood and anxiety disorders including depression. VeraSci experts Dr. Rich Keefe, CEO, and Trina Walker, VP Clinical...

VeraSci is taking all appropriate measures to ensure our staff are prepared to continue business operations over the next several weeks. The governments of the United States and our state of North Carolina have declared a state of emergency and have encouraged...

We wanted to inform you on VeraSci’s current response and policy formation regarding COVID-19, the coronavirus. VeraSci’s office is currently open. We are taking all appropriate measures to ensure our staff are prepared to continue business operations over the next...

The Lancet Digital Health published the article “A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD); a randomized controlled trial” on Monday, February 24. VeraSci CEO Dr. Rich Keefe was a co-author on this article. The article...

True to the source. True to the science. High quality translations for life science companies at a world class standard. VeraSci Global Language Solutions, the translation and cultural adaptation arm of VeraSci, an innovative scientific services and technology...

Testing Industry-Grade Wearable Devices for Real-Time Functional Assessment. VeraSci’s Innovation Lab led by Dr. Alexandra Atkins has begun evaluating the ease of use, sensitivity, and reliability of two industry-grade wearable devices for the real-time capture of...

VeraSci, a leading provider of innovative scientific and technology services, announces the addition of a new service offering, Value Consulting, a HEOR and HTA consulting service line, addressing the emerging need to demonstrate the pharmacoeconomic value of novel...

VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that they have received an FDA grant to conduct further research on the VRFCAT, their proprietary functional capacity assessment. The VRFCAT has recently been accepted...

VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that their proprietary functional capacity assessment, the VRFCAT has officially been accepted into the FDA’s COA Qualification Program.

VeraSci, a leading provider of innovative scientific and technology services, announced today that William P. Horan, PhD will join the company as Vice President of Clinical Science. In this role, Dr. Horan will use his expertise in cognition, clinical neuroscience,...